HealthcareServices

Global Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026–2035: Key Forecasts and Growth Areas

March 2, 2026March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the prostate cancer nuclear medicine diagnostics market from 2026–2035 with trusted insights from The Business Research Company

How is the Prostate Cancer Nuclear Medicine Diagnostics Market size predicted to change over the forecast window of 2026–2035?

The prostate cancer nuclear medicine diagnostics market size has seen rapid expansion in recent years. It is forecast to increase from $0.99 billion in 2025 to $1.13 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. The historical growth of this market can be attributed to the expansion of nuclear medicine infrastructure, increased use of radiotracers in oncology, the availability of gamma camera and pet imaging systems, rising prostate cancer diagnosis rates, and growth in hospital-based imaging services.

The market for nuclear medicine diagnostics in prostate cancer is projected to experience swift expansion over the coming years. This market is anticipated to reach $1.84 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. Several factors are contributing to this growth during the forecast period, including progress in radiopharmaceutical innovation, an increasing need for accurate cancer staging instruments, the broadening scope of personalized oncology diagnostics, heightened investment in integrated imaging platforms, and the expanding utilization of molecular imaging methods. Key trends identified for this period encompass the growing acceptance of PET and SPECT imaging techniques, the increasing application of radiopharmaceutical diagnostics, a rising requirement for functional cancer imaging, the development of hybrid imaging technologies, and a stronger emphasis on precise disease staging.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15906&type=smp

Which Drivers Are Contributing To The Expansion Of The Prostate Cancer Nuclear Medicine Diagnostics Market?

An increase in the incidence of prostate cancer is anticipated to drive the expansion of the prostate cancer nuclear medicine diagnostics market moving ahead. Prostate cancer manifests in the prostate, a compact, walnut-sized gland in men responsible for generating seminal fluid, which serves to nourish and transport sperm. This increasing occurrence of prostate cancer can be attributed to an aging demographic, evolving lifestyle habits, and inherited genetic predispositions. The use of prostate cancer nuclear medicine diagnostics offers crucial data, empowering medical professionals to provide more accurate, potent, and tailored treatment for individuals afflicted with prostate cancer. For example, in February 2024, the World Health Organization, a Switzerland-based specialized agency focusing on global public health, reported that more than 35 million new cancer cases are forecast by 2050, marking a 77% surge compared to the estimated 20 million cases in 2022. Consequently, the growing prevalence of prostate cancer is a key driver for the prostate cancer nuclear medicine diagnostics market.

What Segment Categories Are Covered In The Prostate Cancer Nuclear Medicine Diagnostics Market?

The prostate cancer nuclear medicine diagnostics market covered in this report is segmented –

1) By Type: Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)

2) By Test Type: Preliminary Tests, Confirmatory Tests

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT, Hybrid SPECT Or CT Imaging

2) By Positron Emission Tomography (PET): PET Or CT Imaging, PET Or MRI Imaging

What Trends Are Reshaping The Dynamics Of The Prostate Cancer Nuclear Medicine Diagnostics Market?

Major companies operating in the prostate cancer nuclear medicine market are focusing on the development of sophisticated solutions like targeted alpha-particle radiotherapy to boost treatment precision and minimize unwanted side effects. Targeted alpha-particle radiotherapy utilizes radioactive isotopes that release alpha particles, allowing for the selective elimination of cancer cells while safeguarding healthy tissue, thereby offering a highly localized and effective treatment alternative. For example, Actinium Pharmaceuticals Inc., a US-based developer of antibody radiation conjugates and other targeted radiotherapies, introduced ATNM-400, which incorporates actinium-225 (Ac-225) radiotherapy, in March 2025. This therapy targets a non-prostate-specific membrane antigen, which is found in elevated levels in prostate cancer patients, providing an option for individuals who are resistant to PSMA-targeted therapies such as Pluvicto. Key attributes of ATNM-400 include its application of the alpha-particle emitter Ac-225, which can decrease off-target effects compared to beta-particle therapies, and its ability to target a distinct cancer marker to expand treatment applicability. The launch includes preclinical data demonstrating biodistribution, imaging, and efficacy assessments across different dose levels, with additional results expected from Pluvicto-resistant prostate cancer models. ATNM-400 is poised to advance precision radiotherapy and improve therapeutic options for patients battling prostate cancer.

Which Key Players Are Driving Competition In The Prostate Cancer Nuclear Medicine Diagnostics Market?

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Biopharma Global Inc, Alliance Medical Ltd, SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Isotope Technologies Garching ITG, Jubilant Pharma Limited, Blue Earth Diagnostics Inc, Institute Of Isotopes Co Ltd, Radiopharm Theranostics, Bracco Diagnostic Inc, NCM USA LLC, ABX Advanced Biochemical Compounds GmbH, Theragnostics Ltd, SpectronRx Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Which Region Is Projected To Lead The Prostate Cancer Nuclear Medicine Diagnostics Market During The Forecast Period?

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2025. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prostate Cancer Nuclear Medicine Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15906&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Nuclear Medicine Diagnostics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Prostate Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795